Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Nov;59(11):2797-803.
doi: 10.1007/s10620-014-3230-3. Epub 2014 Jun 5.

Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women

Pai-Jong Stacy Tsai  1 , Ann Chang, Seiji Yamada, Naoky Tsai, Marguerite Lisa Bartholomew
Affiliations
Clinical Trial

Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women

Pai-Jong Stacy Tsai et al. Dig Dis Sci. 2014 Nov.

Abstract

Background: Antiviral therapy in addition to immunoprophylaxis at birth has been shown to further reduce perinatal transmission of hepatitis B virus (HBV) in highly viremic women.

Aims: The aim of this study was to describe the use of tenofovir disoproxil fumarate (TDF) prophylaxis to reduce maternal HBV DNA levels and potentially vertical transmission in highly viremic women.

Methods: After receiving IRB approval, we performed a retrospective chart review of mothers positive for hepatitis B surface antigen (HBsAg) who delivered between 2009 and 2012. We identified women with HBV DNA levels ≥6 log copies/mL who were treated with TDF in pregnancy.

Results: There were 22 women identified. The majority were of Micronesian ethnicity. All were negative for hepatitis C antibody and HIV infection. The median gestational age of TDF initiation was 31 weeks with a median duration of treatment of 45 days. There was a reduction in median HBV DNA levels from baseline 9.0 ± 2.0 to 5.4 ± 1.1 log copies/mL after treatment. There were five (22.7 %) preterm deliveries and five (22.7 %) cesarean deliveries. All infants received immunoprophylaxis at birth. Postnatal HBsAg testing at 9-12 months was available for 13 infants, 12 of which were negative. There was one case of perinatal transmission.

Conclusions: This is the second published case series to date on the use of TDF prophylaxis in HBV mono-infected, highly viremic mothers. This series suggests the use of TDF in pregnancy reduces maternal HBV DNA levels and is well tolerated.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Pai-Jong Stacy Tsai, Marguerite Lisa Bartholomew, and Ann Chang report no conflict of interest.

Figures

Fig. 1
Fig. 1
Patient selection
See this image and copyright information in PMC

References

    1. World Health Organization. [Accessed October 9, 2013];Hepatitis B fact sheet. 2013 http://www.who.int/mediacentre/factsheets/fs204/en/
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. - PMC - PubMed
    1. Center for Disease Control and Prevention. [Accessed October 9, 2011];Viral hepatitis statistics and surveillance. 2011 http://www.cdc.gov/hepatitis/Statistics/index.htm.
    1. Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics. 2003;111:1192–1197. - PubMed
    1. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683. - PubMed

Publication types

MeSH terms

LinkOut - more resources